|
1）Benson LN, Nykanen D, Collison A. Radiofrequency perforation in the treatment of congenital heart disease. Catheter Cardiovascular Interv. 2002; 56: 72-82
|
|
|
|
|
2）Schwartz MC, Glatz AC, Dori Y, et al. Outcomes and predictors of reintervention in patients with pulmonary atresia and intact ventricular septum treated with radiofrequency perforation and balloon pulmonary valvuloplasty. Pediatr Cardiol. 2014; 35: 22-9
|
|
|
|
|
3）Lamers L, Garn B, Ellsworth E, et al. Decreased incidence of right-ventricular outflow tract complications using a retrograde snare technique for radiofrequency pulmonary valve perforation. Pediatr Cardiol. 2012; 33: 1275-80
|
|
|
|
|
|
4）Justino H, Benson LN, Nykanen DG. Transcatheter creation of an atrial septal defect using radiofrequency perforation. Catheter Cardiovasc Interv. 2001; 54: 83-7
|
|
|
|
|
|
5）Du Marchie Sarvaas GJ, Trivedi KR, Hornberger LK, et al. Radiofrequency-assisted atrial septoplasty for an intact atrial septum in complex congenital heart disease. Catheter Cardiovasc Interv. 2002; 56: 412-5
|
|
|
|
|
|
6）Hill SL, Mizelle KM, Vellucci SM, et al. Radiofrequency perforation and cutting balloon septoplasty of intact atrial septum in a newborn with hypoplastic left heart syndrome using transesophageal ICE probe guidance. Catheter Cardiovasc Interv. 2005; 64: 214-7
|
|
|
|
|
|
7）Hijazi ZM. New device for percutaneous closure of Aortopulmonary collaterals. Catheter Cardiovasc Interv. 2004; 63: 482-5
|
|
|
|
|
|
8）Tabori NE, Love BA. Transcatheter occlusion of pulmonary arteriovenous malformations using the AMPLATZER Vascular Plug II. Catheter Cardiovasc Interv. 2008; 71: 940-3
|
|
|
|
|
|
9）Fisher G, Apostolopoulou SC, Rammos S, et al. Transcatheter closure of coronary arterial fistulas using the new AMPLATZER vascular plug. Cardiol Young. 2007; 17: 283-7
|
|
|
|
|
|
10）Ferro C, Rossi UG, Bovio G, et al. The AMPLATZER vascular plug 4: Preliminary Experience. Cardiovasc Intervent Radiol. 2010; 33: 844-8
|
|
|
|
|
|
11）Ewert P, Schubert S, Peters B, et al. The CP stent—short, long, covered—for the treatment of aortic coarctation, stenosis of pulmonary arteries and caval veins, and Fontan anastomosis in children and adults: an evaluation of 60 stents in 53 patients. Heart. 2005; 91: 948-53
|
|
|
|
|
|
12）Zhao W, Li F, Zhou AQ, et al. Cheatham-Platinum stent implantation for pulmonary artery stenosis in children and adolescents: immediate and mid-term outcome. World J Pediatr. 2010; 6: 337-41
|
|
|
|
|
|
13）Agnoletti G, Marini D, Ou P, et al. Cheatham platinum (CP) and Palmaz stents for cardiac and vascular lesions treatment in patients with congenital heart disease. EuroIntervention. 2009; 4: 620-5
|
|
|
|
|
|
14）Riede FT, Flosdorff P, Dähnert I. Emergency covered stent implantation for rupture of the ascending aorta after balloon angioplasty. Catheter Cardiovasc Interv. 2010; 76: 1044-6
|
|
|
|
|
|
15）Baspinar O, Irdem A, Sivasli E, et al. Comparison of the efficacy of different sized AMPLATZER duct occluders ( I, II, II AS ) in children weighting less than 10 kg. Pediatr Cardiol. 2013; 34: 84-94
|
|
|
|
|
|
16）Kenny D, Morgan GJ, Bentham JR, et al. Early clinical experience with a modified AMPLATZER ductal occlude for transcatheter arterial duct occlusion in infants and small children. Catheter Cardiovasc Interv. 2013; 82: 534-40
|
|
|
|
|
|
17）Vincent RN, Ravieie AA, Diehl HJ. Single-center experience with the HELEX septal occluder for closure of atrial septal defects in children. J interv Cardiol. 2003; 16: 79-82
|
|
|
|
|
|
18）Jones TK, Latson LA, Zahn E, et al. Results of the U.S. multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defects. J Am Coll Cardiol. 2007; 49: 2215-21
|
|
|
|
|
|
19）Javois AJ, Rome JJ, Jones TK, et al. Results of the U.S. Food and Drug Administration continued access clinical trial of the GOREHELEX septal occluder for secundum atrial septal defect. JACC Cardiovasc Interv. 2014; 7: 905-12
|
|
|
|
|
|
20）Roymanee S, Promphan W, Tonklang N, et al. Comparison of the Occlutech Figulla septal occluder and AMPLATZER septal occluder for atrial septal defect device closure. Pediatr Cardiol. 2015; 36: 935-41
|
|
|
|
|
|
21）Holzter R, Balzer D, Cao QC, et al. Device closure of muscular ventricular septal defects using the AMPLATZER muscular ventricular septal defect occlude. Immediate and mid-term results of a US registry. J Am Coll Cardiol. 2004; 43: 1257-63
|
|
|
|
|
|
22）Carminati M, Butera G, Chessa M, et al. Investigators of the European VSD Registry. Transcatheter closure of congenital ventricular septal defect: results of the European Registry. Eur Heart J. 2007; 28: 2361-68
|
|
|
|
|
|
23）El Said HG, Bratincsak A, Gordon BM, et al. Closure of perimembranous ventricular septal defects with aneurysmal tissue using the AMPLATZER Duct Occluder I: lessons learned and medium term follow up. Catheter Cardiovasc Interv. 2012; 80: 895-903
|
|
|
|
|
|
24）Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000; 356: 1403-5
|
|
|
|
|
|
25）Cheatham JP, Hellenbrand WE, Zahn EM, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation. 2015; 131: 1960-70
|
|
|
|
|
|
26）Kenny D, Hijazi ZM, Kar S, et al. Perutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary position: early phase 1 results from an international multicenter clinical trial. J Am Coll Cardiol. 2011; 58: 2248-56
|
|
|
|
|